Proctor J W, Lewis M G, Mansell P W
Can J Surg. 1976 Jan;19(1):12-9.
Immunotherapy of cancer is of interest to oncologists because it is specifically directed to cancer cells, sparing normal cells. While it is ineffective in most patients, especially those with widespread metastatic disease, it occasionally produces good results. Each of the available methods has inherent problems and, recently, attempts have been made to overcome some of these. There is a strong case for small-scale experimental trials in highly selected groups of patients who are intensively investigated for their immunologic status in relation to their tumour. Despite the lack of success in general, immunotherapy still appears to have a future as an adjunct to existing therapy in order to control as much as to cure residual tumour.
癌症免疫疗法受到肿瘤学家的关注，因为它专门针对癌细胞，而不损伤正常细胞。虽然它对大多数患者无效，尤其是那些患有广泛转移性疾病的患者，但偶尔也会产生良好的效果。每种可用的方法都有其固有的问题，最近，人们已尝试克服其中一些问题。对于经过严格挑选、并针对其与肿瘤相关的免疫状态进行深入研究的患者群体，进行小规模的实验性试验是很有必要的。尽管总体上缺乏成功，但免疫疗法作为现有疗法的辅助手段，在控制乃至治愈残留肿瘤方面似乎仍有前景。
